Dxcover Ltd Joins in Recognizing July 17 2024 as #GBMDay in the US
2024年7月17日 - 8:00PM
ビジネスワイヤ(英語)
Company establishing US operations in Nashville
TN
Dxcover Limited, a clinical-stage diagnostics company pioneering
its multi-omic spectral analysis (MOSA-Dx) for early detection of
solid tumor cancers, joins in recognizing July 17, 2024 as
“Glioblastoma Awareness Day” in the US. The 118th Congress recently
passed a bi-partisan resolution calling for greater public
awareness of glioblastoma, honors those who have been impacted by
the disease and supports efforts which improve the long-term
prognosis for and quality of life for those impacted by the
disease. The entirety of the Resolution can be found here
https://www.congress.gov/bill/118th-congress/senate-resolution/735/text.
While considered a rare cancer, Glioblastoma (GBM) is one of the
most complex, deadly and treatment-resistant cancers, accounting
for approximately 50% percent of all primary malignant brain tumor
diagnoses each year. Once diagnosed, GBM survival rates are often a
few months and, despite new therapeutic efforts, have not improved
over decades. Unfortunately, therapeutic treatments have not yet
significantly improved patient survival nor quality of life.
Chief Executive Officer Professor Matthew J. Baker said,
"Dxcover was founded to enable the earliest detection of cancer. We
believe that the combination of Dxcover’s multi-omic spectral
analysis and machine learning will lead to the greatest impact on
patient recovery, lifespan and quality of life post-diagnosis. We
recently launched our EMBRACE study, our UK and pan-Europe 2,200
patient performance evaluation of the Dxcover® Brain Cancer Liquid
Biopsy which will enable CE marking and provide a much-needed tool
for patients."
The company has published in both retrospective and prospective
clinical studies the Dxcover PANAROMIC™ platform’s detection of
brain tumors as small as 0.2 cm3. The company is seeking clinical
trial partners to demonstrate the platform’s brain and other solid
tumor early detection capabilities in the United States.
About Dxcover Limited
The Dxcover PANAROMIC platform utilizes multi-omic spectral
analysis to detect cancer. This technology goes beyond traditional
methods by analyzing signals missed by current cell-free DNA
testing. Dxcover's PANAROMIC platform has achieved impressive
results, including 99% specificity for early-stage tumors and
validation in over 3,000 patient samples across various cancers.
This versatile platform can be adapted for high sensitivity (ruling
out cancer) or high specificity (ruling in cancer), making it a
valuable tool for clinicians. Additionally, Dxcover's platform is
patented in the US, EU, and China. It recently incorporated in the
US and is in the process of establishing US operations in Nashville
TN.
For further information https://www.dxcover.com/science
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717274849/en/
Stacy Chick 609-480-1839 Stacy.chick@dxcover.com